INTERNAL MEMORANDUM — LAZARUS PHARMACEUTICALS — BIOETHICS REVIEW BOARD — CLASSIFICATION: SIGMA-7

RE: Feasibility Assessment — Accelerated Growth Cloning for Therapeutic Organ Supply

Per the Board's request, this memo summarizes the current state of the accelerated growth cloning program (codename GARDEN) as of Q3 2219. The program has successfully produced 1,247 viable tissue-matched clone bodies at developmental stages ranging from neonatal to approximately 12 years biological age. Growth acceleration protocols have been refined to achieve a 12-year biological age in approximately 14 months of tank gestation, with a viability rate of 89%. Organ harvest success rates remain above 94% for cardiac, hepatic, and renal tissues.

The Board has asked me to address the accountability gap identified in the Q2 audit. Of the 1,247 viable bodies produced since program inception, 1,203 have been processed through standard organ harvest protocols. The remaining 44 bodies — 3.5% of total production — are classified as "disposition unknown." These units were logged as viable at their final developmental checkpoint but do not appear in harvest records, disposal records, or any downstream processing documentation. They are simply absent from the system.

I want to be transparent about what this means. Forty-four clone bodies, biologically aged between 4 and 12, with full neural development, functional autonomic systems, and no BCI implantation, are unaccounted for. If these bodies achieved consciousness during the growth process — which our neural monitoring data suggests is possible after month 9 of accelerated gestation — they would be indistinguishable from naturally born children of the same apparent age, with the exception of having no birth records, no medical history, and no identity documentation. Their growth plate structures would show subtle anomalies consistent with accelerated early development, but this would only be detectable through targeted radiological examination.

The mathematical implications are straightforward. If the GARDEN program has been operating at similar scale across multiple Lazarus facilities — and I have no visibility into operations outside this site — and if the disposition gap is consistent, then the total number of unaccounted bodies could range from several hundred to several thousand, depending on the number of active sites. This figure is consistent with the scale of the demographic anomaly reported in recent GLMZ census data.

This memo constitutes my formal recommendation that the Board conduct a full audit of all GARDEN program sites and reconcile the disposition records. I am not alleging that clone bodies have been deliberately released or have escaped. I am stating that we cannot prove they haven't. The distinction matters. — Dr. Yuki Abara-Singh, Senior Bioethicist, Lazarus Pharmaceuticals. [MEMO AUTHENTICATED BY THREE INDEPENDENT CRYPTOGRAPHIC ANALYSTS. LAZARUS PHARMACEUTICALS HAS ISSUED A STATEMENT DENYING THE EXISTENCE OF ANY PROGRAM MATCHING THIS DESCRIPTION.]